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Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the world’s population. Systemic treatments,
including methotrexate and cyclosporin, are associated with potential hepatotoxicity, due to either direct liver damage or
immunosuppression or both immunomediated and a direct liver injury; therefore, treatment of patients with psoriasis poses a
therapeutic challenge. The aim of this minireview is to help clinicians in the management of psoriatic patients who develop signs
of liver dysfunction. To find relevant articles, a comprehensive search was performed on PubMed, EMBASE, and Cochrane with
appropriate combinations of the following keywords being considered: viral hepatitis, nonalcoholic fatty liver disease, psoriasis,
hepatotoxicity, drug toxicity, cholestasis, and autoimmune liver diseases.
1. Introduction
Psoriasis world prevalence was attested to be 125 million
people, constituting a great problem in public health and so a
main challenge. Psoriasis presents a geographical variation in
prevalence, spacing from0.91% in theUSA to 8.5% inNorway
[1] that may be due to differences in climate, genetic back-
ground, and exposome [2]. Notwithstanding higher latitudes,
countries show the higher prevalence andAfrica andAsia dis-
play the lower one; the estimation could be affected also by the
lack of solid and cooperative archives. Psoriasis is a chronic
inflammatory disease classically thought to affect only skin,
but recently discovered to afflict systemically the whole
body, including the gastrointestinal district. Likewise, other
more celebrated systemic inflammatory diseases, psoriasis
creates and maintains an inflammatory microenvironment
in which proinflammatory mediators spread from lesional
skin to other district insulting different and distant tissues
and giving the rationale of the so-called comorbidities [3].
Coherent with previous studies, psoriasis is actually thought
to have a potential and intrinsic hepatolesivity. This idea was
recently supported by the first mouse-model of hepatitis in
imiquimod-induced psoriasis [2]. Furthermore, an increased
body of evidences suggests a possible association with the
classical autoimmune hepatic disorders, such as neutrophilic
cholangitis or primary cirrhosis [4]. Systemic treatments,
including methotrexate (MTX) and cyclosporin (CyA), are
associated with potential hepatotoxicity, due to either direct
liver damage or immunosuppression or both immunome-
diated and a direct liver injury [5]; therefore, treatment of
patients with psoriasis poses a therapeutic challenge. This
minireview will briefly touch upon some points of liver
involvement in psoriatic patients.
2. Evidence Acquisition
To find relevant articles, a comprehensive search was per-
formed on PubMed, EMBASE, and Cochrane with appro-
priate combinations of the following keywords being consid-
ered: viral hepatitis, nonalcoholic fatty liver disease, psoriasis,
hepatotoxicity, drug toxicity, cholestasis, and autoimmune
liver diseases. Recent articles were in priority. Primary
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sources were meta-analyses, systematic reviews, and original
articles in order to achieve the highest possible level of
evidence.
3. Psoriasis and Liver Biochemistry
Disturbance because of Psoriasis
Idiopathic liver biochemistry disturbance in psoriasis is
not a nosographic entity well described in the literature.
Tula et al. retrospectively reviewed 518 psoriasis patients, of
these the liver biochemistry disturbance and the potential
relation with the most common risk factors (obesity, diabetes
mellitus, alcohol consumption, hepatotoxicmedications, dys-
lipidemia, infectious hepatitis) were evaluated [6]. Elevation
of liver enzymes was defined idiopathic in patients without
an identified risk factor: 4% of mild-moderate and 8% of
severe elevation of liver function tests [6]. However, in our
opinion, this percentage (4–8%) cannot be interpreted as
idiopathic because the authors (for the retrospective nature
of the study) did not evaluate all the possible causes of
hypertransaminasemia (e.g., autoimmune disorders, celiac
disease, Hemochromatosis, and Wilson’s disease) [6].
4. Disturbance Because of the Treatment of
Psoriasis (Drug-Induced Liver Dysfunction)
Drug-induced liver injury (DILI) is a leading cause of
emergency liver transplantation; it ranges fromasymptomatic
elevation of liver enzymes to acute liver failure. The elevation
of liver enzymes in psoriasis patients is mainly associated
with consumption of liver toxic substances (57%) followed by
nonalcoholic fatty liver disease (NAFLD) (22%) [6]. Different
drugs taken by patients with psoriasis are reported to be
hepatotoxic. The most common antipsoriatic drugs associ-
ated with elevation of liver enzymes are MTX and Acitretin
(ACIT). In most cases, liver enzyme levels are only mildly
elevated [6]. MTX has been considered to be one of the main
causes of elevation of liver enzymes, in psoriatic patients, for
several years. It is a systemic medication and immune system
suppressant, used to treat moderate-to-severe psoriasis and
psoriatic arthritis (PsA). MTX is the most frequently used
disease-modifying and rheumatic drugs (DMARDs) with
over 70% of PsA patients still taking the drug. MTX rarely
causes clinically significant hepatotoxicity and it is more
common in PsA patients, instead pulmonary toxicity with
MTX is found more often in rheumatoid arthritis (RA)
[7]. In a retrospective study, conducted from 2000 to 2009
in a tertiary dermatology center in Malaysia, sixty-six of
710 (9.3%) patients with psoriasis were prescribed MTX
throughout the 10-year period. Among them57.6%developed
deranged transaminases, with six requiringMTXwithdrawal
due to hepatotoxicity [8]. In a retrospective cohort review
among patients of a large health maintenance organization
in Israel who were diagnosed with either RA (𝑛 = 119) or
psoriasis (𝑛 = 690) and who had purchased at least one dose
of MTX, liver function analyses were performed serially in
these patients during the follow-up. Both groups had hepatic
enzyme elevation; the predisposing factors predictive of liver
damage were female gender and a higher cumulative dose of
MTX (hazard ratios, 1.46 and 1.07, resp., 𝑝 < 0.001). Age,
concurrent diseases, and type of disease had no influence
on susceptibility to liver damage. No significant differences
between psoriasis PsA and RA patients was found [9]. A
previous prospective study, involving 550 RA patients and
69 PsA patients on MTX, showed that PsA patients have a
higher incidence of hepatotoxicity compared to RA patients.
In this study, alcohol consumption did not correlate with
hepatic injury (mean 5.15 versus 6.6 alcohol units/week
consumed by RA and PsA patients, resp.) [10]; the use of
folate supplements in patients treated with MTX reduces the
incidence of hepatotoxicity and gastrointestinal intolerance
without impairing the efficacy of MTX [11]. An ethanolic
extract of leaves of Piper betle (Paan) Linn is a promising
antioxidant-mediated hepatoprotective agent in decreasing
the MTX-induced toxicity. Future studies are needed to
confirm the therapeutic efficacy [12]. Actually, MTX liver
toxicity appears to be associated with underlying metabolic
syndrome and NAFLD [13]; a recent meta-analysis showed a
significant difference in moderate elevation of liver enzymes
in obese patientswith PsA treatedwithMTXversus nonobese
patients [14]. Furthermore, obesity is reported to display
a role in increasing the risk of liver toxicity from MTX
and CsA [15]. The elevation of liver enzymes was evaluated
in RA and PsA patients enrolled in the Consortium of
Rheumatology Researchers of North America (CORRONA).
Liver enzymes abnormalities were identified when the upper
limits of normal (ULN) were either 1- or 2-fold times above:
elevations > 2x ULN occurred in 1-2% of patients on MTX
or leflunomide (LEF) monotherapy compared with 5% with
the combination. Liver enzymes elevations were developed
in 14–35% of RA/PsA patients, initiating DMARD therapy.
The risks were incrementally greater in those with PsA and in
those receivingMTX plus LEF [16]. Cumulative dose ofMTX
does not seem to be associated with a progression to liver
cirrhosis [17]. Transient elastography and FibroTest could be
effective noninvasive tools for monitoring the progression to
liver cirrhosis in patients [18]. Recently, researchers propose
to reduce the use of liver biopsy in patients with elevation
of liver enzymes if transient elastography or FibroTest and
Procollagen III peptide is performed. But this strategy is
not validated in prospective studies [19]. MTX may be used
in association with ACIT, CsA, prednisone, and antitumor
necrosis factor alpha (TNF-𝛼). The association of MTX with
ACIT in the past it has been the object of a warning regarding
the potential hepatotoxicity of the drug interactions. The
ACIT and MTX combination therapy for psoriasis is well
tolerated [20] and recently has shown higher effectiveness
and less liver fibrosis [21]. ACIT is a synthetic retinoid used
for severe extensive psoriasis; it is associated with abnormal
liver function test findings and toxic hepatitis in 1.5% of
patients [22]; ACIT-associated liver toxicity and apoptosis
is possibly related to mitochondrial dysfunctions [23]. CsA
hepatotoxicity is rare event [24]; the underlying mechanism
is probably due to an oxidative stress and redox imbalance
demonstrated in rat’s hepatocytes [25]. Liver injury, although
uncommon, has been observed in some patients treated
with medications that inhibit the actions of TNF-𝛼 [5, 26].
Ustekinumab, an IL-12/23 blocker, is cause of an uncommon
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Table 1: Comparison of liver toxic substances in psoriatic patients.
Drug Potential toxicity Type of Injury In hepatic insufficiency Increased risk
Methotrexate ↑ Oxidative stress NA NAFLD/Obesity, Leflunomide
Acitretin ↑ Mitochondrial dysfunctions NA NA
TNF inhibitors ↑ Autoimmune hepatitis NA NA
IL-12/23 blocker ↑ NA Safe NA
IL-17 blockers NA NA NA NA
Cyclosporin Rare Oxidative stress Safe Obesity
Fructus Psoraleae ↑ Liver lipid metabolism NA NA
NA: not applicable.
and mild liver injury. From a hepatic point of view, the
drug appears safe, even in patients with preexisting liver
disease and those who have developed altered liver function
previously with other drugs [27]. Fructus Psoraleae (FP)
is used by herbalists for the treatment of postmenopausal
osteoporosis, vitiligo, and psoriasis. It is used alone, or in
combination with other herbs, in some countries in the
form of proprietary medicine. It is recognized as one of the
emerging liver toxic substances [28]. A case of hepatitis and
jaundice is associated with ingestion of Lotus-f3 submitted to
a Norwegian regional pharmacovigilance center. A 56-year-
old woman with PsA developed increased liver enzymes and
jaundice 3 weeks after having started to take the product [29].
Table 1 shows comparison of liver toxic substances in psoriatic
patients [7, 13, 16, 22, 23, 25–28, 30–32].
5. Psoriasis and Hepatitis B Virus Infection
Chronic hepatitis B affects about 3-4% of the world popula-
tion, which results in being HBsAg positive. Notwithstand-
ing, the number of people (around two billion) is far larger
who has been exposed during his lifetime to hepatitis B virus
(HBV), becoming occult carrier [33–35]. HBV infection has
been directly linked with many skin disorders; however, the
connectionwith psoriasis is indirect and it relies on the risk of
HBV reactivation (HBVr) during immunosuppressive drug
therapy (ISDT) [36, 37]. HBVr is not a univocal syndrome,
ranging from clinically inapparent laboratory alterations to
life-threatening liver injury [38]. It can occur both in patients
with overt chronic HBV infection (HBsAg positive) and in
occult HBV carriers [39, 40]. Literature data mostly focus on
patients with solid tumors and hematological malignancies,
yielding guidelines and recommendations to prevent and
manage HBVr in these settings [41]. Nonetheless, HBVr may
also involve patients undergoing ISDT because of inflamma-
tory bowel disease and rheumatologic and/or dermatologic
conditions [42].Thus, screening for HBV all the patients who
are about to commence an ISDT, and establishing the possible
risk ofHBVr, ismandatory in order to implement appropriate
preventive measures [43, 44]. Antiviral prophylaxis is war-
ranted in case of high or moderate risk of HBVr and a tight
monitoring is necessary for remaining patients [43]. Unan-
swered questions include the exact duration of prophylaxis
which usually started 2–4 weeks before the initiation of ISDT
and prolonged at least for 6–12 months after the last dose
of the ISDT [45]. As for subjects suffering from psoriasis,
the problem arises especially when criteria for moderate-
to-severe disease are met, requiring either conventional
DMARDs (cDMARDs) or biological ones (bDMARDs) [46].
Among the cDMARDs, ACIT is not an immunosuppressive
agent, although its potential liver toxicity limits its use in
subjects with overt viral hepatitis [47, 48]. CsA is associated
with a moderate risk of HBVr both in HBsAg-positive and
in HBsAg-negative patients [43, 48], whereas MTX is linked
with low risk of HBVr [43, 49]. Among the bDMARDs, the
class encompassing the major number of active agents is
represented by TNF inhibitors: the more potent ones (inflix-
imab, adalimumab, golimumab, and certolizumab) pose a
high risk of HBVr inHBsAg-positive patients and amoderate
risk in occult HBV carriers; the less potent ones (etanercept)
imply a moderate risk in the first group and even lower in
the latter [43]. TNF inhibits viral replication and elicits T-
lymphocyte cytotoxic response: thus the rationale explained
the risk of HBVr carried by anti-TNF drugs [50, 51]. HBVr as
a consequence of anti-TNF agents has been mainly reported
in patients suffering from diseases different from psoriasis,
such as inflammatory bowel disease and rheumatic disorders
[52]. Unfortunately, data regarding use of TNF inhibitors and
risk of HBVr specifically in psoriatic patients are derived
from small series, often retrospective, not seldom includ-
ing both subjects with only dermatological manifestations
and individuals with PsA [53–55]. About HBsAg-positive
patients, data come fromvery limited experienceswith regard
to sample size [49, 53]. In the most recent study, recruiting
10 patients treated with adalimumab (all with detectable
viremia at baseline apart from one), no HBVr was observed;
all of them were under antiviral prophylaxis [56]. In smaller
series, mainly focusing on patients previously classified as
“inactive carriers” and currently defined as with a “HBeAg
negative chronic HBV infection” (positivity to anti-HBe,
HBV DNA usually <2,000 IU/ml but sometimes fluctuating
slightly over this threshold, however not >20,000 IU/ml),
HBVr was observed only when no antiviral prophylaxis had
been adopted [33]. In detail, Cho et al. described 3 cases of
reactivation out 7 patients under etanercept [57].There is just
one case describing the use of an anti-TNF agent (infliximab)
in a patient with concomitant diffuse psoriasis and chronic
active HBV infection: the sequential use of lamivudine
and entecavir was successful in preventing HBVr and even
achieving viremia negativization [58]. Other bDMARDs have
targets such as IL-17A (secukinumab) and IL-12/IL-23 (ustek-
inumab) [59]. In general, these cytokine-based therapies are
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deemed to pose amoderate risk of HBVr regardless of HBsAg
status [46]. IL-17A has role in the inflammatory process
accompanying chronic B hepatitis [60]. Clinical trials on
secukinumab showed no increased risk of HBVr [61]. In
conclusion, although evidence does not rely on high-quality
studies, all patients with psoriasis who are about to undergo
an ISDT need to be screened for HBV; the decision to start a
prophylaxis depends on the risk of viral reactivation, which
is higher in HBsAg-positive patients treated with anti-TNF
agents as well as ustekinumab [62]. Table 2 summarizes the
risk gradient of HBVr with different drug [45, 48, 63, 64].
6. Psoriasis and Hepatitis C Virus Infection
Hepatitis C virus (HCV) infection affects about 200 million
people worldwide, being a major health problem [65]. HCV
infection is associated with a high spectrum of extrahepatic
disorders, including dermatological manifestations such as
Sicca syndrome and lichen planus [66]. Some reports suggest
a link between HCV and psoriasis as well [67]. In a case-
control study, matching with a 1 : 2 ratio and involving
12,502 subjects, the prevalence of HCV psoriatic patients
was twofold compared with the control group (1.03% versus
0.56%,𝑝 = 0.001); atmultivariate analysis, psoriasiswas asso-
ciated with HCV and not with HBV, although also HBV was
more frequent in the group of cases [68]. Although the patho-
genesis of psoriasis remains not fully elucidated, an increased
body of evidences showed a possible infectious trigger in
genetically susceptible patients [69, 70]. Traditionally guttate
form of psoriasis is believed to be triggered by infections,
especially Streptococcus related [71]; however also recent stud-
ies onHCV-positive psoriatic patients start to extend the con-
cept of infectious trigger also to other psoriasis subtypes such
as plaque one [1]. Imafuku et al. reported that HCV infection
contributes to develop late onset psoriasis and that HCV-
positive patients have a double risk of psoriasis than unin-
fected ones [72]. Albeit the role of HCV as trigger in psoriasis
iswell known, fewdata are present about the role ofHCVafter
psoriasis development. Chun et al. found increased mRNA
levels of cathelicidin, Toll-like receptor (TLR)-9 and IFN-
𝛾 in both lesional and nonlesional skin of HCV-positive
patients with psoriasis compared to HCV-negative psoriatic
patients. These data, together with an increased level of IFN-
𝛾 in lesional skin than in nonlesional one in HCV-positive
psoriatic patients, may address to a key role of HCV also
in maintaining and amplify psoriasis inflammatory pathway.
The proposed theory that HCV implement the expression of
cathelicidin and IFN-𝛾 in keratinocytes upon injury stimuli
and activate Plasmacytoid dendritic cells to produce IFNs
and finally initiate and maintain a Th1/Th17 inflammatory
response in the skin, capable of developing psoriasis [73].
Likewise, also psoriasis can contribute to chronicize HCV
infection. Despite its role in autoimmune diseases, such as
psoriasis, IL-17 is also implicated in privileging the evolution
from acute to chronic phase of HCV infection. In particular,
the acute phase is lack of expansion of either CD4+ or
CD8+ T cells producing IL-17, in contrast with chronic HCV
patients that display statistically more Th17 compared to
peripheral blood [74]. Beyond the controversial issue of a
causal relationship, especially in areas with moderate-high
HCV endemicity the concrete problem is how to manage
patients suffering from psoriasis and with concomitant HCV
infection [75]. One point to be addressed is the risk of acute
exacerbation and/or reactivation of chronic HCV infections
in patients undergoing an ISDT. Actually, the magnitude of
the problem is not as relevant as for HBV [76]. Moreover,
the definition of these entities is not universally standardized:
however, in the setting of cancer patients, acute exacerbation
was defined as a 3-fold or greater increase in serumALT level,
whereas reactivation was defined as an increase in viremia
of at least 1 log10 IU/ml [77]. The aforementioned systematic
review found HCV reactivation only in 3 out 97 patients
with psoriasis under bDMARDs treatment, without evidence
of hepatitis exacerbation (3.1%) [78]. Among bDMARDs,
most data concern TNF antagonists: in HCV patients with
psoriasis [79], their use appears safe, although sporadic cases
of hepatocellular carcinoma (HCC) have been reported [49].
This occurrence affected cirrhotic patients: considering that
cirrhosis by any cause is itself a remarkable prooncogenic
risk factor, it is difficult to establish the role played by TNF
inhibitors, which, however, should be used with caution
in psoriatic patient with advanced liver disease [49, 79];
cDMARDs seem safe in HCV patients with psoriasis as for
reactivation [49]. Unfortunately, to the best of our knowledge,
specific guidelines on management of psoriatic patients
under biological treatment andwith concomitantHCV infec-
tion are lacking [80]. Therefore, the screening should rely
on the rules set for the general population, according to the
international guidelines: first, serology (HCV antibody) and
then virology (serumHCV-RNA) tests [81]. In case of current
HCV infection (HCV antibody reactive and serum HCV-
RNA detectable), appropriate counselling and referral to
an infectious diseases/hepatology specialist are fundamental
steps [82]. If no treatment decisions are made, a prudent
and reasonable choice could be a close monitoring of liver
function test as well as viremia, namely, each 3–6 months
[49]. To our knowledge, there is no study that evaluate the
possibility of HCV reactivation during psoriasis systemic
treatments. Nowadays, data about Direct-Acting Antiviral
Agents (DAAs) treatments in psoriatic patients is still lacking;
further studies are needed to investigate this aspect and try
to answer to the question [83]. In Table 3, we describe the
suspected drug-drug interactions of approved FDA therapies
to treat HCV infection and systemic antipsoriatic therapies.
This description is based on relevant data, in the public
domain, of the University of Liverpool [84]. No data are
available of the following antipsoriatic drugs: fumaric acid,
certolizumab, brodalumab, guselkumab, ixekizumab, secuk-
inumab, calcipotriene, apremilast, ustekinumab, infliximab,
adalimumab, tofacitinib, and golimumab (Table 3).
7. Hepatocellular Carcinoma and Psoriasis
Th-17 cells are currently thought to have a bridging role
between innate and adaptive immunity and by long a dys-
function in this lineage may support the genesis of autoim-
munity and cancer [85, 86]. Despite the universally accepted
concept that HCV can provoke HCC [87], the eventual
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Table 3: Drug-drug interactions expected of HCV therapies and systemic anti-psoriatic therapies.
Prednisone Betamethasone Methotrexate Cyclosporine Acitretin Etanercept
Daclatasvir NIE NIE PI NIE NIE PWI
Elbasvir/grazoprevir NIE NIE PI DNC NIE PWI
Glecaprevir/pibrentasvir NIE NIE PI PI NIE PWI
Ombitasvir/paritaprevir/ritonavir PI PI NIE PI NIE PWI
Ombitasvir/paritaprevir/ritonavir/dasabuvir PI PI NIE PI NIE PWI
Simeprevir PI PI NIE DNC NIE PWI
Sofosbuvir NIE NIE NIE NIE NIE PWI
Sofosbuvir/ledipasvir NIE NIE NIE NIE NIE PWI
Sofosbuvir/velpatasvir NIE NIE PI NIE NIE PWI
Sofosbuvir/velpatasvir/voxilaprevir NIE NIE DNC DNC NIE PWI
DNC: do not coadminister; NIE: no interaction expected; PI: potential interaction; PWI: potential weak interaction.
correlation between psoriasis and HCC remains still open.
Some cytokines, as IL-6, TNF-𝛼, and VEGF, typically overex-
pressed both in skin and in serum of psoriatic patients have a
pivotal role also in HCC [88]. IL-6 is a pleiotropic cytokines
involved in chronic inflammation and liver carcinogenesis
and found to be related to hepatic function and tumor
progression and determine HCC patient survival [89]. TNF-
𝛼 playing an inflammatory role in regulating hepatocyte pro-
liferation and regeneration and its overexpression is related
to tumor progression because of released to nonparenchymal
cells in HCC [90]. Vascular-endothelial growth factor is
highly expressed in HCC as well, a typical hypervascular
tumor [91]. The advanced stages of HCC displayed also high
levels IL-10 [89], in contrast with psoriasis where IL-10 is
usually low [92]. However, Aroucha et al. described that HCC
were associated with high TNF-𝛼/IL-10 ratio, supposing that
the unbalanced production of these cytokines should address
to a progression of liver disease in HCV patients [93].
8. Nonalcoholic Fatty Liver Disease and
Nonalcoholic Steatohepatitis
NAFLD encompasses a continuum spectrum of liver con-
ditions from the simple steatosis to steatohepatitis (NASH),
with the risk to evolve to cirrhosis and hepatocellular carci-
noma [94]. The prevalence of NAFLD in general population
spaces from 10% to 25%, while, among psoriatic patients,
the rate is even more, ranging from 17% to 65% depending
on the considered studies [95–100]. NASH occurs in 20% of
NAFLDpatients [96] and globally displays a greater tendency
to evolve in psoriatic patients [101]. In fact patients with
NAFLD/NASH and psoriasis have higher Psoriasis Area
Severity Index (PASI) and C-reactive protein than patients
with only psoriasis [98–100]. In add, psoriasis is described
to be an important predictor of advanced liver fibrosis [99].
From a pathogenic point of view NAFLD represents the
tissue-related manifestation of metabolic syndrome, aspect
confirmed by both metabolic profile and epidemiological
data of patients with psoriasis and PsA [102]. Recent studies
state that metabolome, performed on liver samples, differs,
respectively, from healthy controls to NAFLD patients and
may be crucial to discriminate NAFLD patients with a
tendency to progress to NASH [103]. Assessing the inflam-
matory background main actors in psoriasis and NAFLD,
many proinflammatory cytokines, such as IL-1𝛽, TNF-𝛼, and
IL6, are in common and may create, sustain, and maintain
the three stages of NAFLD, namely, inflammation, insulin
resistance, and lipid accumulation [104]. TNF-𝛼 and IL-6
not only drive keratinocyte proliferation and differentiation
but also increase insulin resistance and promote proin-
flammatory cytokines release. Microvascular remodeling in
psoriatic skin is conducted mainly by IL-17 and TNF-𝛼, that
is contemporary due to steatosis and fibrosis of the liver.
IL-8, the main neutrophilic chemo attractor, is significantly
high and contributes to promote the homing of neutrophils
and maintain the proinflammatory microenvironment in
both districts. Adiponectins are in the complex altered, to
testimony that the lipidic metabolism is deeply perturbed
by a chronic systemic status of inflammation. Coherent
with the previously discussed data, psoriasis and NAFLD
share a common proinflammatory background and may
sustain and amplify each other. Empirical evidence arrives
from a study that assessed 81 patients with plaque psoriasis,
metabolic syndrome, and NAFLD treated for 24 weeks with
etanercept, a TNF-blocker, or PUVA therapy. Only the group
that undergo etanercept obtained a significant reduction
of AST/ALT ratio, C-reactive protein, homeostasis model
assessment (HOMA) and an increase toQuantitative Insulin-
Sensitivity Check Index (QUICK) [105]. These data seem to
highlight the role of inflammation both as a promoter and as
a maintainer of NAFLD and psoriasis, leading to the concept
that a systemic intervention is needed to contemporary care
and limit both conditions.
9. Autoimmune Hepatitis
Autoimmune hepatitis (AIH) is a chronic inflammatory liver
disease that recognizes the aberrant autoaggressive immu-
nity against self-hepatocyte antigens as first step [95]. Treg
ineffective response, selective IgG elevation, and autoreactive
T cells are the three mainstays of AIH and together cause
the histological evidences of a progressive necroinflam-
matory interface hepatitis, clinically highlighted by hyper-
transaminasemia, hypogammaglobulinemia, and circulating
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autoantibodies [106]. It can coexist with several liver diseases
and extrahepatic manifestation, first of all psoriasis among
the immune-mediated ones [107]. In fact, as in psoriasis,
the involvement of Th17 seems to be crucial in AIH as
described by mouse models where the expression of IL-17
was higher than controls in liver specimens and sera; further-
more, the administration of anti-IL-17 neutralizing antibod-
ies markedly improves the hepatic necrosis and decreases the
hypertransaminasemia [108].
10. Primary Biliary Cirrhosis
Primary Biliary Cirrhosis (PBC) is a chronic inflammatory
autoimmune disease primarily involving cholangiocytes of
the interlobular bile ducts in the liver with an unexplained
geographical variation of prevalence [109]. The diagnosis
is made if two of the three criteria are fulfilled: presence
of specific-autoantibodies (anti-mitochondrial antibodies,
abnormal cholestasis indexes for more than 6 months,
chronic nonsuppurative cholangitis followed by progressive
bile duct destruction [96, 110]. As summarized in the table,
the axis Th1/Th17 is strictly involved in causing and main-
taining PBC, as well as psoriasis [111]. Pathogenetic data
are confirmed also by epidemiological studies that quantify
the prevalence of psoriasis in 13% of PBC patients [109].
Prince et al. described in a case-control study a higher
risk of PBC in psoriatic patients than in healthy controls
[112]. Weak associations with other autoimmune disease are
ascertained [109]. Occasionally PBCmay occur together with
AIH or PSC leading to the clinical characteristic overlap
syndrome strictly coexisting with other autoimmune dis-
eases, especially psoriasis [113, 114]. These data suggest once
more the concept of mosaic of autoimmunity, stating that,
in genetically predisposed individuals with an abnormal
immune response, several autoimmunity disturbances may
develop due to the complex interaction between genetic,
hormonal, immunological, and environmental factors that
are combined in different ways [115].
11. Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis (PSC) is a cholestatic liver
and biliary tract disease associated with chronic inflamma-
tion of the biliary epithelium, histologically characterized by
intra- and extrahepatic biliary structures, and fibrosis [116].
It eventually may evolve in secondary biliary cirrhosis and
malignancy [116]. PSC is still a condition characterized by
a high rate of misdiagnosis, partially due to the fact that
approximately 40–50% of patients are asymptomatic [117].
Due to the fact that the rarity of the condition both prevalence
and incidence remain inaccurate, epidemiological data show
a strong predilection for male gender [118]. PSC notably is
coexistent to autoimmune and autoinflammatory conditions,
namely, inflammatory bowel diseases and psoriasis [118] and
presents common HLA susceptibility loci [119]. The patho-
genesis of PSC remains still unclear; however, the current
hypothesis orients to an abnormal response to a gut pathogen
in a host with both altered biliary mucosal milieu and a
genetic predisposition [118]. The weight of microbiota is still
in exam; however, an increased body of evidencemay suggest
a possible link between skin and gut microbiota and a pivotal
role in modulating inflammation [120]. Recently a mice
model relates alterations of gut microbiota to imiquimod-
induced psoriasis by altering the T cell [121].
12. Neutrophilic Cholangitis
Neutrophilic Cholangitis (NC) is an entity recently identified
and characterized by a predominantly neutrophilic infiltra-
tion of biliary ducts resulting in cholestasis, without sclerotic
aspects [122]. No data of incidence and prevalence are present
due to the extreme rarity of the disease. The systematic
parallel course hypertransaminasemia and psoriasis flares,
in a patient negative for viral hepatitis, autoantibodies, and
hepatotoxic drug intake, orients to NC. The instrumental
confirmation with MRCP that evidences dilatations of intra-
hepatic bile ducts with or without strictures of the common
bile duct; however, histology remains the gold standard
for diagnosis of NC [123]. NC appears to be related to
neutrophilic-diseases, especially psoriasis [122]. Remarkably,
peripheral blood neutrophilia is usually present. As expected,
IL-8, the main chemoattractive for neutrophils, has been
observed in NC [124] in keratinocytes from skin lesions of
psoriasis vulgaris and generalized pustular psoriasis [125] and
in synovial lesions of PsA [126], suggesting a key role in the
pathogenesis of NC among patients with psoriasis.
13. Hepatic Sarcoidosis (HS)
Sarcoidosis is a multisystem disease of unknown aetiology
that is seen as a key histological findings noncaseating
granulomas. It rarely affects also the liver; hepatic sarcoidosis
may present as asymptomatic hepatic granulomas to clini-
cally evident disease with cholestasis or, in advanced cases,
cirrhosis and portal hypertension. Occasionally HS may
occur together with other inflammatory diseases, namely,
psoriasis [127–130].
14. Conclusions
The bridge between skin and liver was starting to delineate
and psoriasis could be a great pathognomonic example of
it. Liver can be affected, directly or indirectly, by psoriasis;
consequently, a great attention to the liver profile is manda-
tory. In accordance with the guidelines, actually almost
exclusively psoriatic patients that undergo a systemic therapy
are routinely checked for liver affections. Finally, this review
aims first to underline thewide spectrumof liver diseases that
can co-occur in psoriatic patients and secondary to suggest a
routine liver check also in psoriatic patient without a systemic
therapy-psoriasis related.
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